Genetic tracking could predict leukemia relapse, guide treatment
NCT ID NCT02756962
Summary
This study is testing whether tracking specific cancer-related genetic mutations in patients' blood can help doctors better predict who is at high risk of their leukemia returning. Researchers are following 107 adults with acute myeloid leukemia (AML) who are in remission after initial treatment. They're comparing survival rates between patients whose mutations have cleared and those who still have them, to see if this genetic information can help decide between standard chemotherapy or a stem cell transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Florida
Gainesville, Florida, 32608, United States
-
University of Rochester
Rochester, New York, 14642, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.